Verastem Oncology doses first patient in Target-D 203 phase 2 registration-directed trial of versus-7375 oral Kras G12d (on/off) inhibitor for Kras G12d-mutated metastatic colorectal cancer
Verastem Oncology doses first patient in Target-D 203 phase 2 registration-directed trial of Versus-7375 oral Kras G12d (on/off) inhibitor for Kras G12d-mutated metastatic colorectal cancer
Verastem - initiates treatment in all three Target-D phase 2 trials
VSTM•
